Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Michinori Togawa"'
Publikováno v:
Allergology International, Vol 66, Iss 2, Pp 317-325 (2017)
Background: Bilastine, a novel non-sedating second-generation H1-antihistamine, has been widely used in the treatment of allergic rhinoconjunctivitis and urticaria with a recommended dose of 20 mg once daily in most European countries since 2010. We
Externí odkaz:
https://doaj.org/article/e064c287d1f04af980c4b85f1c8f7bac
Autor:
Kimihiro Okubo, Minoru Gotoh, Mikiya Asako, Yasuyuki Nomura, Michinori Togawa, Akihiro Saito, Takayuki Honda, Yoshihiro Ohashi
Publikováno v:
Allergology International, Vol 66, Iss 1, Pp 97-105 (2017)
Background: Bilastine, a novel non-sedating second-generation H1 antihistamine, has been approved in most European countries since 2010. This study aimed to evaluate the superiority of bilastine over placebo in Japanese patients with perennial allerg
Externí odkaz:
https://doaj.org/article/1f1c9045036143dbbc34bd4925c24804
Publikováno v:
Allergology International, Vol 66, Iss 1, Pp 123-131 (2017)
Background: Environmental exposure chambers have been used to expose subjects to aeroallergens to investigate the efficacy of prophylactic treatment with symptomatic agents in Japan. We first examined the therapeutic effect of bilastine (BIL), a nove
Externí odkaz:
https://doaj.org/article/cf1cb1438b2f4aebab38609940988a93
Publikováno v:
Allergology International, Vol 66, Iss 2, Pp 317-325 (2017)
Background: Bilastine, a novel non-sedating second-generation H1-antihistamine, has been widely used in the treatment of allergic rhinoconjunctivitis and urticaria with a recommended dose of 20 mg once daily in most European countries since 2010. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bea8ece647df7683dc33503912225411
http://www.sciencedirect.com/science/article/pii/S1323893016301113
http://www.sciencedirect.com/science/article/pii/S1323893016301113
Publikováno v:
Allergology International, Vol 66, Iss 1, Pp 123-131 (2017)
Background Environmental exposure chambers have been used to expose subjects to aeroallergens to investigate the efficacy of prophylactic treatment with symptomatic agents in Japan. We first examined the therapeutic effect of bilastine (BIL), a novel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecf626add8e7973858e340b462c0d07d
http://www.sciencedirect.com/science/article/pii/S132389301630096X
http://www.sciencedirect.com/science/article/pii/S132389301630096X
Autor:
Michitaka, Shichijo 1, Yasuo, Shimizu 2, Kenju, Hiramatsu 2, Michinori, Togawa 1, Naoki, Inagaki 1, Kenzo, Takagi 2, Hiroichi, Nagai 1, *
Publikováno v:
In Japanese Journal of Pharmacology 1999 79(4):501-504
Publikováno v:
The Journal of Dermatology
A number of second‐generation non‐sedating antihistamines are used in clinical practices over the world. However, long‐term safety and efficacy have not been proved high level evidence based medicine. We have performed an open‐label, multicen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dc9c711e1b970538bd35b3f13268b1b
https://pubmed.ncbi.nlm.nih.gov/27862227
https://pubmed.ncbi.nlm.nih.gov/27862227
Autor:
Yoshihiro Ohashi, Akihiro Saito, Takayuki Honda, Mikiya Asako, Yasuyuki Nomura, Kimihiro Okubo, Minoru Gotoh, Michinori Togawa
Publikováno v:
Allergology International, Vol 66, Iss 1, Pp 97-105 (2017)
Background: Bilastine, a novel non-sedating second-generation H1 antihistamine, has been approved in most European countries since 2010. This study aimed to evaluate the superiority of bilastine over placebo in Japanese patients with perennial allerg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a02f9445fc6bfee0bb3453822e4d0e3
Publikováno v:
Nippon Jibiinkoka Gakkai Kaiho. 120:1381-1382
Objective Bilastine is a novel second-generation antihistamine. This open-label, single-arm, phase III study evaluated the safety and efficacy of long-term treatment with bilastine in Japanese patients with seasonal (SAR) or perennial allergic rhinit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01be5fa0b22bea534c0de1bfdb982087
https://doi.org/10.3950/jibiinkoka.120.1381
https://doi.org/10.3950/jibiinkoka.120.1381
Autor:
Kouichi Ohmori, Naomasa Asaka, Tatsuzo Oka, Shozo Yamada, Mamoru Kiniwa, Eiji Sasaki, Hiroyuki Kakuo, Michinori Togawa
Publikováno v:
Arzneimittelforschung. 60:564-570
TAS-203 (2-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-5-(1H-1,2,4-triazol-1-yl)-1H-benzimidazole, CAS 223909-92-0) is a novel phosphodiesterase 4 (PDE4) inhibitor that has been found to have good anti-inflammatory effects and low emetogenic activity in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19e76a20aee24227ae1494311adef46c
https://doi.org/10.1055/s-0031-1296326
https://doi.org/10.1055/s-0031-1296326